This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / BioAge Labs Class Action Lawsuit
Business class action

BioAge Labs Class Action Lawsuit

Analysis based on 12 articles · First reported Feb 03, 2025 · Last updated Feb 13, 2025

Sentiment
-70
Attention
4
Articles
12
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The market is impacted by the significant decline in BioAge Labs' stock price following the discontinuation of its lead drug candidate. This event highlights the risks associated with pharmaceutical development and can lead to increased scrutiny of similar companies' IPO disclosures.

Biotechnology Legal Services
Event Summary

BioAge Labs, a publicly traded company, is facing a class action lawsuit initiated by The Gross Law Firm on behalf of shareholders who purchased stock during its initial public offering on or about September 26, 2024. The lawsuit alleges that BioAge Labs discontinued its lead product candidate, azelaprag, from its STRIDES Phase 2 trial on December 6, 2024, due to safety concerns regarding elevated liver transaminase levels. This discontinuation led to a substantial drop in BioAge Labs' stock price, from $20.09 to $4.65 per share, between December 6 and December 7, 2024. The lawsuit claims that BioAge Labs had highlighted azelaprag's potential in obesity therapy with incretin drugs at the time of its IPO, less than three months prior to the discontinuation. The deadline for shareholders to seek lead plaintiff appointment is March 10, 2025.

Key Actions
100 BioAge Labs discontinued trial
Entities Involved
priv
BioAge Labs
BioAge Labs is facing a class action lawsuit due to the discontinuation of its lead product candidate, azelaprag, which caused a significant drop in its stock price.
Importance 100.0 Sentiment -90.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.